Dicot Pharma AB (STO:DICOT)
Sweden · Delayed Price · Currency is SEK 0.2088
+0.0062 (3.06%)
At close: Aug 14, 2026
Dicot Pharma AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 56.2 | 69.19 | 113.42 | 47.34 | 9.38 | 30.33 |
Cash & Short-Term Investments | 56.2 | 69.19 | 113.42 | 47.34 | 9.38 | 30.33 |
Cash Growth | -39.44% | -39.00% | 139.58% | 404.88% | -69.08% | 49.20% |
Other Receivables | 5.4 | 2.38 | 3.47 | 2.3 | 1.14 | 1.01 |
Receivables | 5.4 | 2.38 | 3.47 | 2.3 | 1.14 | 1.01 |
Inventory | 9.3 | 8 | 5.38 | 3.4 | 1.49 | - |
Prepaid Expenses | - | 5.89 | 1.35 | 0.5 | 0.34 | 0.4 |
Other Current Assets | - | - | - | -0 | - | - |
Total Current Assets | 70.9 | 85.46 | 123.62 | 53.54 | 12.35 | 31.74 |
Property, Plant & Equipment | - | - | - | 0.01 | 0.02 | 0.03 |
Total Assets | 70.9 | 85.46 | 123.62 | 53.56 | 12.37 | 31.77 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | - | 6.12 | 6.84 | 4.54 | 3.42 | 2.58 |
Accrued Expenses | - | 4.87 | 4.05 | 3.98 | 1.19 | 0.66 |
Other Current Liabilities | 12.4 | 1.12 | 1.07 | 0.64 | 2.41 | 0.19 |
Total Current Liabilities | 12.4 | 12.11 | 11.96 | 9.16 | 7.01 | 3.42 |
Total Liabilities | 12.4 | 12.11 | 11.96 | 9.16 | 7.01 | 3.42 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 14.1 | 14.07 | 12.45 | 5.72 | 17.14 | 12.86 |
Additional Paid-In Capital | 339.1 | 339.31 | 299 | 180.76 | 86.15 | 81.67 |
Retained Earnings | - | -280.02 | -199.79 | -142.09 | -97.93 | -66.18 |
Comprehensive Income & Other | -294.7 | - | - | - | - | - |
Shareholders' Equity | 58.5 | 73.36 | 111.67 | 44.39 | 5.36 | 28.35 |
Total Liabilities & Equity | 70.9 | 85.46 | 123.62 | 53.56 | 12.37 | 31.77 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash (Debt) | 56.2 | 69.19 | 113.42 | 47.34 | 9.38 | 30.33 |
Net Cash Growth | -39.44% | -39.00% | 139.58% | 404.88% | -69.08% | 49.20% |
Net Cash Per Share | 0.03 | 0.04 | 0.10 | 0.09 | 0.08 | 0.47 |
Filing Date Shares Outstanding | 2,009 | 2,009 | 1,779 | 817.56 | 137.1 | 102.9 |
Total Common Shares Outstanding | 2,009 | 2,009 | 1,779 | 817.56 | 137.1 | 102.9 |
Working Capital | 58.5 | 73.36 | 111.67 | 44.38 | 5.34 | 28.32 |
Book Value Per Share | 0.03 | 0.04 | 0.06 | 0.05 | 0.04 | 0.28 |
Tangible Book Value | 58.5 | 73.36 | 111.67 | 44.39 | 5.36 | 28.35 |
Tangible Book Value Per Share | 0.03 | 0.04 | 0.06 | 0.05 | 0.04 | 0.28 |
Machinery | - | - | - | 0.04 | 0.04 | 0.04 |